<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00228982</url>
  </required_header>
  <id_info>
    <org_study_id>CR005038</org_study_id>
    <secondary_id>BAP00154</secondary_id>
    <nct_id>NCT00228982</nct_id>
  </id_info>
  <brief_title>Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind Study of Ceftobiprole Versus Comparator in the Treatment of Complicated Skin and Skin Structure Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basilea Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basilea Pharmaceutica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril
      versus a comparator in the treatment of patients with complicated skin and skin structure
      infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ceftobiprole medocaril is a cephalosporin antibiotic with anti-MRSA (Methicillin-Resistant
      Staphylococcus Aureus) activity. Ceftobiprole medocaril is not yet approved for the treatment
      of complicated skin and skin structure infections. This is a randomized, double-blind,
      multicenter study of ceftobiprole medocaril plus placebo versus a comparator to assess the
      effectiveness and safety of ceftobiprole medocaril in patients with complicated skin and skin
      structure infections. The patients will be randomized to ceftobiprole medocaril plus placebo
      or a comparator. The primary endpoint is the clinical cure rate of ceftobiprole medocaril at
      the test-of-cure visit. The patients will receive either ceftobiprole medocaril plus placebo
      or a comparator for 7 to 14 days (unless extended at discretion of medical monitor).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical outcome (cure, failure, not evaluable) at 7-14 days after the end of therapy.</measure>
    <time_frame>7 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiological outcome at 7-14 days after the end of therapy. Clinical and microbiological outcome at late follow-up visit. Evolution of signs and symptoms of disease. Time to clinical cure. Safety and tolerability evaluations during the study.</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">784</enrollment>
  <condition>Skin Diseases, Infectious</condition>
  <condition>Skin Diseases, Bacterial</condition>
  <condition>Staphylococcal Skin Infections</condition>
  <arm_group>
    <arm_group_label>Ceftobiprole medocaril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ceftobiprole medocaril 500mg q12h as 1h infusion, 7-14d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vancomycin 1g q12h as 1h infusion, 7-14d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftobiprole medocaril</intervention_name>
    <arm_group_label>Ceftobiprole medocaril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <arm_group_label>Vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of an infection consistent with complicated skin and skin structure
             infections.

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to any study medication

          -  Any known or suspected condition or concurrent treatment contraindicated by the
             prescribing information

          -  Previous enrollment in this study

          -  Treatment with any investigational drug within 30 days before enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Mexico</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2005</study_first_submitted>
  <study_first_submitted_qc>September 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2005</study_first_posted>
  <last_update_submitted>July 25, 2012</last_update_submitted>
  <last_update_submitted_qc>July 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Complicated Skin Infections</keyword>
  <keyword>Infectious Skin Diseases</keyword>
  <keyword>Bacterial Skin Diseases</keyword>
  <keyword>Staphylococcal Skin Infections</keyword>
  <keyword>Cephalosporin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Skin Diseases, Infectious</mesh_term>
    <mesh_term>Staphylococcal Skin Infections</mesh_term>
    <mesh_term>Skin Diseases, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Ceftobiprole</mesh_term>
    <mesh_term>Ceftobiprole medocaril</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

